An interventional study of transcranial current stimulation and Sham stimulation in Insomnia, Psychophysiological, sponsored by Zan Wang. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-04.
Sponsored by Zan Wang · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies in Sleep Initiation and Maintenance Disorders with a site in China — 82 open to participants now, 88 under way, 2 of them phase 3. Sleep Initiation and Maintenance Disorders · China.
Among the 198 studies in Sleep Initiation and Maintenance Disorders with a site in China, this one is the 75th largest by planned enrollment of the 162 interventional ones that give a count, is one of 28 that started in 2026, is one of 123 with no phase, reaches primary completion later than 48 of the 87 other live ones, and was the 167th registered.
2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.
Browse Sleep Initiation and Maintenance Disorders studies →82 of the 198 studies in Sleep Initiation and Maintenance Disorders with a site in China are open now. Recruiting first, the newest first:
Sichuan Academy of Medical Sciences · Sites in China
Ages 18–80
China Medical University, China · Sites in China
Ages 60+
Renmin Hospital of Wuhan University · Sites in China
Ages 18–79
Jiangsu Taizhou People's Hospital · Sites in China
Ages 65+
Huazhong University of Science and Technology · Sites in China
Ages 40–65 · Women only
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 6 · Phase 3 9 · Phase 4 13
First in 2006; this study’s year is marked. 28 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 68 across 2,363 interventional studies indexed under Sleep Initiation and Maintenance Disorders.
Median enrollment 88 across the 162 interventional studies, 200 across the 36 observational. Of the 82 that completed or were terminated, 2 (2%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 198 have an industry lead sponsor. The 10 most frequent:
Zan Wang is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Zan Wang has 2 studies filed under Sleep Initiation and Maintenance Disorders — fewer than ten, so there is no comparison to draw.
29 of the studies in Sleep Initiation and Maintenance Disorders with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07738809Capital University of Physical Education and Sports, ChinaEffects of Exercise Intervention on Sleep Quality and Emotional Problems in College Students With Depressive Symptoms | 2026-11 |
| NCT07730762Xijing HospitalA Study of Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) for Insomnia During Pregnancy | 2026-11-30 |
| NCT07340268Zan WangThe Effects of Transcranial Current Stimulation on Insomnia | 2026-11-30 |
| NCT07868224Jiangxi University of Traditional Chinese MedicineValidating Blinding Maintenance of a Sham-Sensitization Control Design for Sensitization Acupuncture Trials | 2026-12-01 |
| NCT07384429YangPanEffects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease | 2026-12-01 |
Add all 29 to your calendar (.ics) → With an account.
Among the 198 studies in Sleep Initiation and Maintenance Disorders with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Effect of transcranial current stimulation on insomnia disorder
Insomnia disorder represents a prevalent clinical challenge, transcranial current stimulation has emerged as a promising noninvasive therapeutic approach; however, its specific effects on neurophysiological mechanisms underlying sleep-related brain structure and functional change, and neurobiological change remain unclear.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
14 daily 20-min, 1.1-mA sessions of active or sham transcranial current stimulation, at the beginning and end of treatment, there is a 30 second period of current fading in and out
Device: transcranial current stimulation
only wore the device and had no stimulation
Device: Sham stimulation
consecutive daily 20-min, 1.1-mA sessions
only wore the device and had no stimulation
Change in global blood-oxygen-level-dependent (gBOLD) signal amplitude
The amplitude of the global blood-oxygen-level-dependent (gBOLD) signal was derived from resting-state functional MRI and reflects the overall magnitude of spontaneous brain activity. Unit of Measure: Z-score
Time frame: 2 weeks and 3 months
Change in resting-state functional connectivity strength
Resting-state functional connectivity strength was calculated as the correlation coefficient between predefined brain regions based on functional magnetic resonance imaging data.
Time frame: 2 weeks and 3 months
Change in amplitude of low-frequency fluctuations
Amplitude of low-frequency fluctuations was calculated from resting-state fMRI to quantify spontaneous neural activity.
Time frame: 2 weeks and 3 months
Change in regional homogeneity
Regional homogeneity was used to assess the synchronization of local spontaneous brain activity
Time frame: 2 weeks and 3 months
Change in phase difference of dynamic cerebral autoregulation
Dynamic cerebral autoregulation was assessed using the phase difference between cerebral blood flow velocity and arterial blood pressure fluctuations. Larger phase differences indicate better autoregulatory function.
Time frame: 2 weeks and 3 months
Change in gain of dynamic cerebral autoregulation
Gain represents the magnitude of cerebral blood flow velocity changes in response to blood pressure fluctuations, with lower gain values indicating more effective autoregulation.
Time frame: 2 weeks and 3 months
the score of Insomnia Severity Index scale
The total score ranges from 0 to 28, and a higher score indicates higher levels of insomnia severity. A score of 8 or greater is the cut point for clinically possible insomnia
Time frame: 2 weeks and 3 months
the score of 14-item Hamilton anxiety rating scale
The total score ranges from 0 to 56, and a higher score indicates higher levels of anxiety symptoms. A score of 7 or greater is the cut point for clinically possible anxiety
Time frame: 2 weeks and 3 months
the score of 17-item Hamilton depression rating scale
tThe total score ranges from 0 to 52, and a higher score indicates higher levels of depression symptoms. A score of 7 or greater is the cut point for clinically possible depression symptom
Time frame: 2 weeks and 3 months
Change in plasma corticotropin-releasing factor (CRF) level
Plasma corticotropin-releasing factor (CRF) concentration was measured as a biomarker of hypothalamic-pituitary-adrenal (HPA) axis activity. Higher levels indicate increased neuroendocrine stress response. Unit of Measure: pg/mL
Time frame: 2 weeks and 3 months
Change in plasma cortisol level
Plasma cortisol concentration was assessed as an indicator of hypothalamic-pituitary-adrenal (HPA) axis function. Higher levels reflect increased physiological stress response. Unit of Measure: μg/dL
Time frame: 2 weeks and 3 months
Change in serum interleukin-6 level
Serum interleukin-6 concentration was measured as a marker of systemic inflammation. Higher levels indicate greater inflammatory activity. Unit of Measure: pg/mL
Time frame: 2 weeks and 3 months
Change in serum brain-derived neurotrophic factor level
Serum brain-derived neurotrophic factor concentration was measured as a biomarker associated with neuroplasticity and neuronal function. Higher levels indicate enhanced neurotrophic activity. Unit of Measure: pg/mL
Time frame: 2 weeks and 3 months
Change in total sleep time (TST) measured by polysomnography
Time frame: 2 weeks and 3 months
Change in sleep onset latency (SOL) measured by polysomnography
Time frame: 2 weeks and 3 months
Change in wake after sleep onset (WASO) measured by polysomnography
Time frame: 2 weeks and 3 months
Not enrolling at this site.
Plan to share: Undecided
Started Jan 2026 (actual). Primary completion is estimated for Nov 2026, 10 months after the start.
Of 1,219 non-industry interventional studies with no phase under Sleep Initiation and Maintenance Disorders, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 35. This study's planned 10 months is below that.
Counting every sponsor, half of 1,297 studies reached it within 15 months; a quarter within 6 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sleep Initiation and Maintenance Disorders →
Zan Wang